558 related articles for article (PubMed ID: 22614006)
1. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
2. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP.
Angus L; Moleirinho S; Herron L; Sinha A; Zhang X; Niestrata M; Dholakia K; Prystowsky MB; Harvey KF; Reynolds PA; Gunn-Moore FJ
Oncogene; 2012 Jan; 31(2):238-50. PubMed ID: 21666719
[TBL] [Abstract][Full Text] [Related]
3. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
5. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract][Full Text] [Related]
8. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
9. KIBRA connects Hippo signaling and cancer.
Swaroop B SS; Kanumuri R; Ezhil I; Naidu Sampangi JK; Kremerskothen J; Rayala SK; Venkatraman G
Exp Cell Res; 2021 Jun; 403(2):112613. PubMed ID: 33901448
[TBL] [Abstract][Full Text] [Related]
10. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.
Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA
J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985
[TBL] [Abstract][Full Text] [Related]
11. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
12. Effects of the hippo signaling pathway in human gastric cancer.
Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB
Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801
[TBL] [Abstract][Full Text] [Related]
13. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway.
Zhang J; Smolen GA; Haber DA
Cancer Res; 2008 Apr; 68(8):2789-94. PubMed ID: 18413746
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
15. AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin.
Couderc C; Boin A; Fuhrmann L; Vincent-Salomon A; Mandati V; Kieffer Y; Mechta-Grigoriou F; Del Maestro L; Chavrier P; Vallerand D; Brito I; Dubois T; De Koning L; Bouvard D; Louvard D; Gautreau A; Lallemand D
Neoplasia; 2016 Jan; 18(1):10-24. PubMed ID: 26806348
[TBL] [Abstract][Full Text] [Related]
16. Kibra is a regulator of the Salvador/Warts/Hippo signaling network.
Genevet A; Wehr MC; Brain R; Thompson BJ; Tapon N
Dev Cell; 2010 Feb; 18(2):300-8. PubMed ID: 20159599
[TBL] [Abstract][Full Text] [Related]
17. The WW domain protein Kibra acts upstream of Hippo in Drosophila.
Baumgartner R; Poernbacher I; Buser N; Hafen E; Stocker H
Dev Cell; 2010 Feb; 18(2):309-16. PubMed ID: 20159600
[TBL] [Abstract][Full Text] [Related]
18. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
20. Kibra and Merlin Activate the Hippo Pathway Spatially Distinct from and Independent of Expanded.
Su T; Ludwig MZ; Xu J; Fehon RG
Dev Cell; 2017 Mar; 40(5):478-490.e3. PubMed ID: 28292426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
